Biotech · Public company · South San Francisco, CA, US
Aligos Therapeutics, Inc.
Ticker ALGS · SEC CIK 0001799448
Track this companyFree. Adds Aligos Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials92 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline13
- ALG-000184Phase 2 · Chronic Hepatitis B InfectionClinicalTrials.gov · fetched Nov 12, 2026
- ALG-055009Phase 2 · NASHClinicalTrials.gov · fetched Nov 12, 2026
- TDFPhase 2 · Chronic Hepatitis B InfectionClinicalTrials.gov · fetched Nov 12, 2026
- ALG-000184Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- ALG-055009Phase 1 · Healthy Volunteer StudyClinicalTrials.gov · fetched Nov 12, 2026
- ALG-055009Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ALG-097558Phase 1 · COVID 19ClinicalTrials.gov · fetched Nov 12, 2026
- AtorvastatinPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- CarbamazepinePhase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- Itraconazole (Sporanox)Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- Pevifoscorvir Sodium (ALG-000184)Phase 1 · Chronic Hepatitis B InfectionClinicalTrials.gov · fetched Nov 12, 2026
- Pevifoscorvir Sodium (ALG-000184)Phase 1 · Chronic Hepatitis B InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- RosuvastatinPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal FunctionPHASE1 · COMPLETED · started Mar 10, 2026ClinicalTrials.gov NCT07342881 · fetched Nov 12, 2026
- Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic FunctionPHASE1 · COMPLETED · started Jan 30, 2026ClinicalTrials.gov NCT07342868 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 15, 2025ClinicalTrials.gov NCT06963710 · fetched Nov 12, 2026
- A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 FormulationsPHASE1 · COMPLETED · started Mar 25, 2025ClinicalTrials.gov NCT06959888 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal FunctionPHASE1 · COMPLETED · started Feb 20, 2025ClinicalTrials.gov NCT06698549 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic FunctionPHASE1 · COMPLETED · started Jan 13, 2025ClinicalTrials.gov NCT06568861 · fetched Nov 12, 2026
- A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy VolunteersPHASE1 · ACTIVE_NOT_RECRUITING · started Jan 9, 2025ClinicalTrials.gov NCT06672900 · fetched Nov 12, 2026
- ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)PHASE2 · COMPLETED · started Apr 1, 2024ClinicalTrials.gov NCT06342947 · fetched Nov 12, 2026
- A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)PHASE1 · COMPLETED · started Nov 3, 2023ClinicalTrials.gov NCT06191991 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 15, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 14, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 5, 2026 · fetched Nov 12, 2026
NIH awards2
- Clinical Development of COVID-19 TherapeuticsFiscal year 2025 · $1.5MNIH RePORTER 75N93023C00052-P00003-9999-1 · fetched Nov 12, 2026
- Clinical Development of COVID-19 TherapeuticsFiscal year 2024 · $1.3MNIH RePORTER 75N93023C00052-P00001-9999-1 · fetched Nov 12, 2026